Department of Ophthalmology, University of Basel, Mittlere Strasse 91, CH-4031 Basel, Switzerland ; Department of Ophthalmology, Hospital of Mülheim an der Ruhr, DE-45468 Mülheim an der Ruhr, Germany.
Department of Ophthalmology, University of Basel, Mittlere Strasse 91, CH-4031 Basel, Switzerland.
EPMA J. 2015 Feb 24;6(1):5. doi: 10.1186/s13167-015-0027-1. eCollection 2015.
The introduction of ophthalmodynamometric measurement of retinal venous pressure (RVP) now permits the quantification, or at least an approximation, of the real pressure in the retinal veins.
We measured the RVP of healthy control subjects, patients with diabetes without diabetic retinopathy (nonDR) and patients with diabetes and diabetic retinopathy (DR).
The mean ± SD RVP for the control, nonDR and DR groups were 23.4 ± 7.33, 22.5 ± 5.78 and 37.7 ± 10.1 mmHg, respectively. In the diabetes patients with DR, the RVP was markedly and significantly increased, and this result was significantly age dependent. RVP was not increased in the group of diabetes patients without DR. In our tested population, diabetes had a minor influence on intraocular pressure.
Regardless of the cause, a marked increase in RVP in diabetes patients with DR is clinically relevant, as it reduces perfusion pressure and increases transmural pressure. The reduced perfusion pressure contributes to hypoxia, and the increased transmural pressure can facilitate retinal edema. Diabetes is an increasing burden, and DR is one of its most severe complications. Strategies to recognize the risk for DR and to develop personalized prevention and therapy therefore have major implications.
ClinicalTrials.gov ID: NCT01771835.
眼动力眼压测量法的引入使得视网膜静脉压（RVP）的量化成为可能，至少可以对视网膜静脉中的真实压力进行近似测量。
我们测量了健康对照组、无糖尿病视网膜病变（非 DR）的糖尿病患者和糖尿病合并糖尿病视网膜病变（DR）的患者的 RVP。
对照组、非 DR 组和 DR 组的平均 RVP 分别为 23.4 ± 7.33、22.5 ± 5.78 和 37.7 ± 10.1mmHg。DR 糖尿病患者的 RVP 明显且显著升高，且该结果与年龄显著相关。无 DR 的糖尿病患者组的 RVP 并未升高。在我们测试的人群中，糖尿病对眼内压的影响较小。
无论病因如何，DR 糖尿病患者的 RVP 显著升高在临床上是相关的，因为它降低了灌注压并增加了跨壁压。降低的灌注压导致缺氧，增加的跨壁压可促进视网膜水肿。糖尿病的负担在不断增加，而 DR 是其最严重的并发症之一。因此，识别 DR 的风险并制定个性化的预防和治疗策略具有重要意义。
ClinicalTrials.gov 标识符：NCT01771835。
